Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged between 18 and 80 years old.
• People who have been diagnosed with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL).
• People whose blood tests show a detectable level of remaining cancer cells (called MRD) using a sensitive laboratory method.
• People who have been taking a BTK inhibitor medication on its own for more than 6 months — specifically one of these four drugs: ibrutinib, zanubrutinib, orelabrutinib, or acalabrutinib.
• People whose cancer has shown at least a partial response to their BTK inhibitor treatment.
• People who are reasonably able to carry out daily activities, as rated by a standard medical scale (confirm with trial site).
• People whose kidneys and liver are functioning adequately, based on blood test results (confirm with trial site).
• People whose bone marrow is producing enough blood cells, based on blood count results (confirm with trial site).
• People whose heart is functioning adequately, with no uncontrolled irregular heartbeat and a heart pumping strength of at least 35% on an ultrasound scan (confirm with trial site).
• People who are able to give informed consent and attend the required follow-up appointments.

Who may not be able to join:

• People whose CLL has transformed into a more aggressive type of lymphoma (called Richter transformation).
• People who have another active cancer that currently requires systemic treatment — although some exceptions may apply for certain previously treated or minor skin cancers (confirm with trial site).
• People who have had major surgery, radiation, chemotherapy, or other cancer treatments within the 3 weeks before starting the study drug.
• People who have had a serious bleeding episode within the past 3 weeks.
• People with an active infection (viral, bacterial, or fungal) that is not under control.
• People who are pregnant or currently breastfeeding.
• People who are known to be HIV positive.
• People with an active hepatitis B infection, based on specific blood markers (confirm with trial site).
• People with active hepatitis C, confirmed by a blood test.
• People with an active, uncontrolled immune condition (such as immune-related anaemia or low platelet counts) that requires a relatively high daily dose of steroid medication within 7 days of starting the study drug (confirm with trial site).
• People who have received any other CLL/SLL treatment alongside their BTK inhibitor before joining the trial.
• People currently taking warfarin or similar blood-thinning medications.
• People who have taken certain medications that strongly affect how the body processes drugs (called strong CYP3A inhibitors or inducers) within 7 days of starting the study drug (confirm with trial site).
• People who have consumed grapefruit, grapefruit juice, Seville oranges, or star fruit within 7 days of starting the study drug.
• People who have previously been treated with venetoclax or any similar drug (called a Bcl-2 inhibitor).
• People who have a condition that prevents them from swallowing or absorbing oral medications properly.

Important: Always verify eligibility with the trial site directly before applying.